As part of our patient-forward mission, we strive to do our best to improve the lives of cancer patients."
Asaf Danziger, Chief Executive Officer
we are dedicated to our mission of making TTFields available to all cancer patients who may benefit from it.
Over a decade ago, we joined Novocure for the opportunity to make a meaningful difference in the lives of cancer patients. Establishing, building and growing an innovative company to provide patients with a new cancer treatment modality demands determination, perseverance and an unwavering focus on the scientific evidence to keep moving forward regardless of the obstacles or resistance that may be encountered. We are passionate about bringing our therapy to all patients who may benefit from it and to developing TTFields for additional solid tumor cancers.
publicationsWe have more than 15 years of research and multiple peer-reviewed publications with pre-clinical data in 15 cancer types and clinical data in eight cancer types.
clinical trialsOur mechanism of action is broadly applicable across a variety of solid tumors.
novocuretrial.comThe science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.